MCTD occupies a position on the CTD spectrum alongside uCTD, with features including Raynaud's, scleroderma, inflammatory rashes, inflammatory myositis, oesophageal involvement, lung involvement, and anti-RNP positivity. ^[3]

A critical concept: MCTD can undergo "diagnostic shift" — over time, the clinical phenotype may evolve predominantly into one defined CTD (e.g., SLE, SSc, or PM). This happens in approximately 10–30% of patients over a decade. This is why some authors question whether MCTD is a distinct entity or a transitional state. ^[4]

• Incidence: approximately 1.9 per 100,000 per year ^[1]
• Prevalence: estimated at 3.8 per 100,000 (varies by population studied)
• It is rarer than SLE or RA individually, but not uncommon in rheumatology practice

• Female predominance: F:M = 3.3–16:1 (most studies cite roughly 9:1, similar to SLE) ^[1]
• Peak onset: 2nd–3rd decades of life (teens to 30s), though can present at any age ^[1]
• Can occur in children (juvenile MCTD) — tends to have more severe myositis and less pulmonary hypertension

• Described across all ethnic groups
• In Hong Kong, MCTD is encountered in rheumatology clinics, though less common than SLE or RA
• Asian patients may have relatively higher rates of pulmonary arterial hypertension (PAH) — a major cause of mortality

• Generally considered to have a favourable prognosis compared with diffuse SSc or severe lupus nephritis ^[4]
• However, prognosis is NOT uniformly benign — PAH and progressive ILD are the major killers
• 10-year survival: approximately 80–90%

• U1 snRNP is part of the spliceosome, the molecular machine that processes pre-mRNA by removing introns (RNA splicing)
• It is composed of U1 RNA bound to several proteins: 70 kDa (U1-70K), A protein, and C protein, plus the common Sm proteins
• In MCTD, antibodies are directed against the 70 kDa protein component of U1 snRNP (anti-U1-70K)
• Since every nucleated cell contains spliceosomes, the autoimmune response can potentially target any tissue

The exact cause of MCTD, like most autoimmune diseases, is unknown. It is best understood as a multifactorial disease arising from the interaction of genetic susceptibility, environmental triggers, and immune dysregulation:

The spectrum of connective tissue disorders ranges from predominant inflammation (SLE) to predominant fibrosis (SSc), with uCTD/MCTD sitting in the middle. ^[3]

Connective tissue diseases associated with Raynaud's phenomenon (in order of frequency): ^[6]

1. Systemic sclerosis
2. MCTD
3. Undifferentiated CTD
4. Sjögren's syndrome
5. Poly-/dermato-myositis
6. Systemic lupus erythematosus
7. Necrotising vasculitis e.g. polyarteritis nodosa
8. Rheumatoid arthritis

Key serological profile of MCTD: ^[4][1]

Anti-ENA (extractable nuclear antigens) are a group of different autoantibodies. Most, except anti-Sm, are not diagnostic of SLE. They may predict clinical manifestations and have prognostic value. Found in many connective tissue disorders. ^[8]

Common early features of connective tissue disease: ^[2]

• CBC: anaemia (~75%), leukopenia, ± thrombocytopenia
• ESR/CRP: elevated (inflammatory markers)
• CK, aldolase, LDH, AST: elevated in myositis (CK most sensitive)
• Renal function, urinalysis: usually normal/mild; proteinuria if membranous nephropathy
• LFTs: usually normal unless hepatic involvement
• Complement C3/C4: normal or elevated (helps distinguish from SLE)

• ANA (speckled pattern), anti-U1 RNP (high titre), anti-dsDNA (low/negative), anti-Sm (negative)
• RF, ACPA
• Full ENA panel (anti-Ro, anti-La, anti-Jo1, anti-Scl70, anti-centromere)
• Antiphospholipid antibodies (anticardiolipin, lupus anticoagulant, anti-β2GP1)

• Nailfold capillaroscopy: abnormal capillary loops indicate CTD ^[7]
• Pulmonary function tests: DLCO (↓ in ILD and PAH), spirometry (restrictive pattern in ILD)
• HRCT chest: for ILD — peripheral/lower zone GGO, septal thickening, ± honeycombing
• Echocardiography: screen for PAH (estimated RVSP), pericardial effusion
• Oesophageal manometry/barium swallow: dysmotility assessment
• EMG/NCS: myopathic pattern if myositis suspected
• MRI muscles: oedema in active myositis
• Muscle biopsy: if myositis diagnosis uncertain

SLE is a chronic, multisystem, autoimmune disease characterised by exacerbation and remission, with predominance in females (9:1). ^[4]

Why it mimics MCTD:

• Both cause malar rash, arthritis, Raynaud's, serositis, cytopenias, and have positive ANA
• Both can have anti-U1 RNP positivity (found in ~30% of SLE patients)
• SLE is part of the spectrum of autoimmune rheumatic diseases alongside MCTD, SSc, PM, DM, Sjögren's, RA, and APS ^[9]

How to distinguish SLE from MCTD:

First-principles explanation: Why does SLE cause severe nephritis but MCTD generally doesn't? In SLE, anti-dsDNA antibodies form immune complexes that preferentially deposit in the glomerular basement membrane and mesangium, activating complement and recruiting inflammatory cells — this is a direct consequence of the specificity of anti-dsDNA for chromatin fragments that have affinity for glomerular structures. In MCTD, anti-U1 RNP immune complexes are less nephrotoxic and tend to deposit in a membranous (subepithelial) pattern if at all, which causes milder disease (proteinuria without the aggressive proliferative destruction).

MCTD can undergo "diagnostic shift" — SLE and MCTD often overlap, and some patients develop full-blown SLE later. ^[2][4]

Systemic sclerosis is a generalised disorder of connective tissue affecting skin and internal organs, characterised by fibrotic arteriosclerosis of peripheral and visceral vasculature, with variable degrees of extracellular matrix accumulation (mainly collagen) in both skin and viscera, and associated with specific autoantibodies, most notably anticentromere and anti-Scl-70. ^[5][10]

Why it mimics MCTD:

• Both cause Raynaud's (nearly universal in SSc), sclerodactyly, oesophageal dysmotility, ILD, and PAH
• SSc and MCTD share the "fibrosis-dominant" end of the CTD spectrum

How to distinguish SSc from MCTD:

First-principles explanation: Why does SSc have renal crisis but MCTD doesn't? SSc renal crisis results from malignant hypertension driven by obliterative vasculopathy of the renal arcuate and interlobular arteries — renin release is massively elevated due to renal ischaemia, creating a vicious cycle. MCTD lacks this degree of renal vascular fibrosis. Additionally, high-dose steroids in SSc can paradoxically trigger renal crisis (mechanism unclear, possibly steroid-induced vasoconstriction), whereas MCTD rarely induces SSc-like renal crisis with steroids ^[4].

The CTD spectrum ranges from predominant inflammation (SLE) through uCTD/MCTD to predominant fibrosis (SSc). ^[3]

PM/DM is a member of the connective tissue disease family, characterised by chronic inflammation of striated muscles (polymyositis) and sometimes the skin (dermatomyositis). Autoantibody associations (e.g., anti-Jo-1, anti-Mi-2) define homogeneous clinical subsets of disease. ^[11]

Why it mimics MCTD:

• Both cause proximal muscle weakness with elevated CK
• Both may have Raynaud's, ILD, and arthralgia
• DM has skin manifestations (though different from SLE-type rashes)

How to distinguish PM/DM from MCTD:

PM/DM may present as myositis associated with other CTD — this is an important subtype. When myositis occurs in the setting of MCTD, it is classified as "overlap myositis" rather than primary PM/DM. The myositis-associated antibodies (anti-Ro, anti-La, anti-Sm, anti-RNP) are suggestive of other CTDs, whereas myositis-specific antibodies (anti-Jo-1, anti-SRP, anti-Mi-2, anti-MDA-5) are only found in primary myositis. ^[12]

Why it mimics MCTD:

• MCTD arthritis is frequently more severe than classic SLE and can present with erosive arthritis with RA-like deformities (swan neck, boutonnière) and even destructive arthritis (arthritis mutilans) ^[1]
• Seropositivity for RA: 70% +ve RF, 50% +ve ACPA — this means MCTD can fulfil RA classification criteria ^[1]

How to distinguish RA from MCTD:

uCTD refers to those with preliminary rheumatic symptoms which do not fit into ANY of the classification criteria of the existing CTDs. ^[7]

uCTD usually comprises one or more of: early Raynaud phenomenon alone, early inflammatory polyarthritis that doesn't fit RA criteria, non-specific rash resembling those in defined autoimmune disease, non-specific ILD, and multiple nonspecific clinical or serological abnormalities (e.g., ANA, RF, anti-Ro/La). ^[7]

Why it mimics MCTD:

• uCTD and MCTD share early features (Raynaud's, arthralgia, positive ANA)
• A patient with early MCTD may initially be classified as uCTD

How to distinguish:

• uCTD lacks the full clinical triad (SLE + SSc + PM features) and may have low-titre or absent anti-U1 RNP
• Positive anti-RNP in a patient with uCTD is a powerful predictor for subsequent evolution into MCTD ^[1]
• With time and accumulating features, uCTD "crystallises" into MCTD or another defined CTD

Sjögren's syndrome is a systemic autoimmune disease with lymphocytic infiltration of exocrine glands, with M:F = 1:9, that can occur as primary or secondary to other CTDs. ^[6]

Why it mimics MCTD:

• Sjögren syndrome occurs in 32% of MCTD patients ^[1] — sicca symptoms are common in MCTD
• Both can cause arthritis, ILD, Raynaud's, and positive ANA/RF

How to distinguish:

• Primary Sjögren's has anti-Ro (SS-A) and anti-La (SS-B) as defining antibodies (not anti-U1 RNP)
• Sjögren's lacks myositis, sclerodactyly, and the broader overlap picture
• Sjögren's has salivary/lacrimal gland enlargement and risk of NHL (5%) ^[6]
• When sicca symptoms occur in MCTD, it is considered secondary Sjögren's

Causes of secondary Raynaud's phenomenon: ^[8]

• Connective tissue diseases: systemic sclerosis (most common), MCTD, uCTD, Sjögren's syndrome, PM/DM, SLE, necrotising vasculitis (e.g., PAN), RA ^[3][8]
• Traumatic: vibration white finger syndrome ^[8]
• Haematological: cold haemagglutinins, cryoglobulinaemia, paraproteinaemia ^[8]
• Hypothyroidism ^[8]
• Drug-induced: beta-blockers, bleomycin ^[8]
• Others: atherosclerosis, thoracic outlet syndrome ^[8]

Primary Raynaud's disease (idiopathic): onset 15–30 years, F > M, usually ANA negative, no tissue ischaemia, normal nailfold capillaroscopy — just requires reassurance ^[4][8]

How to distinguish primary from secondary Raynaud's: Secondary Raynaud's is suspected when onset is > 40 years, male sex, severe with ischaemia/ulceration, asymmetrical, and associated with other CTD signs/symptoms. Nailfold capillaroscopy showing abnormal capillary loops indicates connective tissue disease. ^[8]

Differential diagnoses of polyarthritis: ^[13]

Key distinguishing features of SLE-associated arthritis from MCTD arthritis: ^[13]

• SLE arthritis is classically symmetrical small joint polyarthritis but usually NOT associated with evidence of synovitis; typically non-deforming, non-erosive on plain XR
• MCTD arthritis is erosive with RA-like deformities — much more destructive than SLE arthritis

When myositis dominates the presentation, consider:

IPF only if known causes of ILD (e.g., environmental exposure, connective tissue disease, and drug toxicity) are excluded. ^[14]

When a patient presents with ILD and possible CTD features, the differential includes:

This is the most commonly applied and best-validated set (sensitivity ~63%, specificity ~86%).

Alarcon-Segovia's criteria: A + ≥ 3 of B (must have synovitis or myositis) ^[2]

Why must synovitis or myositis be present? Because Raynaud's + swollen fingers + acrosclerosis alone could be systemic sclerosis. Requiring at least one "inflammatory" feature (synovitis or myositis) forces the diagnosis to include the SLE/PM component that distinguishes MCTD from SSc.

Kahn's criteria: A + ≥ 3 of B (must have Raynaud) ^[2]

Why does Kahn require Raynaud's? Raynaud's phenomenon is the most universal feature of MCTD (~90%) and is the clinical hallmark that places MCTD on the vascular/fibrotic portion of the CTD spectrum. Its mandatory inclusion emphasises the SSc-like vascular component.

Required entry features:

• Anti-U1 RNP positive AND
• Raynaud's phenomenon and/or swollen hands/fingers

Then need at least one feature from each of ≥ 2 of 3 disease categories:

This criterion explicitly tests for the "overlap" nature by requiring features from at least two parent diseases.

The original criteria by Sharp — includes 4 major and 12 minor criteria. Less commonly used in clinical practice due to complexity. Not detailed here but worth knowing exists.

Myositis is defined as 2 out of 3 of: elevated muscle enzymes, EMG findings typical of myositis, and muscle biopsy showing myositis. ^[12]

First-principles explanation of CK: Creatine kinase catalyses the transfer of a phosphate group from phosphocreatine to ADP → ATP, providing rapid energy in muscle cells. CK is normally contained within the myocyte. When the sarcolemma is damaged (by T cell–mediated attack in myositis), CK leaks into the bloodstream. The degree of CK elevation roughly correlates with the extent of active muscle inflammation.

• What it is: Non-invasive microscopic examination of capillary loops at the nail fold (usually 4th finger)
• Why do it: Abnormal capillary loops indicate connective tissue disease ^[8] — this is the single most useful bedside test to distinguish primary Raynaud's (normal capillaroscopy) from secondary Raynaud's (abnormal)
• MCTD findings:
  • Giant capillaries (dilated, tortuous loops)
  • Capillary dropout (avascular areas)
  • Haemorrhages
  • Neo-vascularisation (bushy capillaries)
• Pattern: Typically a "scleroderma pattern" — similar to what you see in SSc

First-principles explanation: Normal nailfold capillaries are uniform, evenly spaced hairpin loops. In CTDs with vascular involvement (SSc, MCTD), endothelial damage leads to capillary destruction (dropout) followed by compensatory capillary dilatation (giant loops). These changes precede clinical scleroderma by months to years and are therefore an early diagnostic clue.

Systemic corticosteroid: mainly for SLE-like features. Classically very responsive to steroid, less so for scleroderma-like features. Dose: 0.25–1 mg/kg/day. ^[2]

Response to steroid: in general, overlap myositis > DM > PM. ^[12] This means myositis in the context of MCTD (which is "overlap myositis") actually responds better to steroids than primary PM or DM. This is one reason MCTD has a relatively good prognosis ^[2].

Steroid-sparing agents: consider HCQ or MTX to reduce steroid burden. ^[2]

Why are these agents "steroid-sparing"? They provide ongoing immunosuppression that allows you to taper and eventually stop steroids while maintaining disease control. The goal is to use steroids for induction (rapid control of inflammation) and these agents for maintenance (sustained remission without steroid toxicity).

Polyarthritis management in SSc context: NSAIDs, antimalarials ± low-dose steroids, MTX if refractory. ^[20] The same principle applies to MCTD arthritis.

Raynaud's management: keep warm, avoid stress and smoking, stop beta-blockers (exacerbate), avoid trauma (finger-prick blood glucose testing), vasodilators: CCB (amlodipine), ARB, PDE inhibitors (sildenafil). ^[4]

First-principles explanation of CCBs in Raynaud's: Vascular smooth muscle contraction requires calcium influx through L-type calcium channels → calcium binds calmodulin → activates myosin light chain kinase → cross-bridge cycling → contraction. CCBs block L-type channels → less calcium entry → less contraction → vasodilation. Dihydropyridine CCBs (amlodipine, nifedipine) are vascular-selective; non-dihydropyridines (verapamil, diltiazem) are cardio-selective and less useful for Raynaud's.

This is the major cause of mortality in MCTD ^[1][2]. Treatment mirrors Group 1 PAH guidelines.

Pulmonary hypertension treatment: vasoactive agents e.g., bosentan, sildenafil, riociguat (sGC sensitizer). ^[4]

SSc treatment for pulmonary hypertension: vasodilators as per Raynaud's; O2, endothelin-1 antagonists, phosphodiesterase 5 inhibitors. ^[21]

Combination therapy: Current guidelines (2022 ESC/ERS) recommend initial dual combination therapy (ERA + PDE5i) for intermediate-/high-risk PAH patients. Triple combination (add prostacyclin pathway agent) for inadequate response.

Why riociguat cannot be combined with PDE5i: Both target the NO-cGMP pathway but at different points — PDE5i prevents cGMP breakdown while riociguat stimulates cGMP production. Together they cause massive cGMP accumulation → profound systemic hypotension. They are never used simultaneously.

ILD management: immunosuppressants (MMF, cyclophosphamide, rituximab, tocilizumab), nintedanib. ^[4]

Treatment of CTD-associated ILD (including MCTD-ILD) is fundamentally different from IPF — immunosuppression IS effective because the ILD has an inflammatory component, unlike IPF which is purely fibrotic.

NSIP management: observe for mild stable disease; immunosuppression for moderate/severe disease. Initial therapy: oral steroid or IV pulse steroid ± azathioprine, MMF. 2nd line: cyclophosphamide, rituximab, calcineurin inhibitor. ^[15]

Why does immunosuppression work in CTD-ILD but not in IPF? CTD-ILD (including MCTD) has an inflammatory alveolitis component — immune cells infiltrate the interstitium, and suppressing this inflammation halts or slows fibrosis. IPF, by contrast, is a disease of aberrant fibroblast activation without significant preceding inflammation — hence anti-inflammatory/immunosuppressive agents are ineffective (and may be harmful — the PANTHER-IPF trial showed harm from prednisone + AZA + NAC in IPF).

Skin management: good skin hygiene, low-dose steroids (avoid high dose), ?methotrexate, D-penicillamine. ^[4]

GI management: GERD — PPI / H2 blockers; dysmotility — prokinetics (e.g., metoclopramide). ^[4]

• Characteristically NO severe renal involvement ^[1]; if mild membranous nephropathy → ACEI/ARB for proteinuria reduction
• ACEI for renal crisis (if it occurs) ^[4] — mechanism: ACEI blocks angiotensin II → reduces efferent arteriolar constriction → lowers intraglomerular pressure → slows GN progression. Also the definitive treatment for SSc renal crisis.
• Avoid high-dose steroid (prednisolone > 10 mg/day) in SSc context ^[4] — though this risk is lower in MCTD, it is prudent to be cautious

PAH (pulmonary hypertension): SOBOE, right heart failure → major cause of mortality. ^[1]

Why does PAH in MCTD not respond to steroids? Because PAH is a structural vascular disease — the intimal proliferation and vascular remodelling are irreversible fibrotic changes, not active inflammation. By the time PAH manifests, the vascular architecture is permanently altered. This is why PAH requires specific vasoactive agents (ERAs, PDE5i, prostacyclins) rather than anti-inflammatory therapy ^[4].

Complications of PAH itself:

• Right heart failure → cor pulmonale → hepatic congestion → cardiac cirrhosis (long-standing)
• Arrhythmias → atrial flutter/fibrillation from right atrial dilatation
• Syncope → from inability to augment cardiac output with exertion
• Sudden cardiac death → from acute RV failure or fatal arrhythmia
• Haemoptysis → from bronchial artery hypertrophy or ruptured pulmonary vessels

ILD (50–66%): ↓DLCO, SSc-like changes on HRCT (peripheral/lower zone septal thickening, GGO). ^[1]

The GC lecture case illustrates MCTD complicated by fibrosing alveolitis. ^[22]

Complications of ILD:

• Respiratory failure → Type 1 respiratory failure (hypoxaemia without hypercapnia) initially; Type 2 in end-stage
• Secondary pulmonary hypertension → chronic hypoxia causes pulmonary arteriolar vasoconstriction (Euler-Liljestrand mechanism), adding to any primary PAH already present
• Recurrent respiratory infections → fibrosed lungs have impaired mucociliary clearance; immunosuppressive treatment further increases susceptibility
• Pneumothorax → rare but possible from ruptured subpleural honeycomb cysts

First-principles: why does ILD cause Type 1 respiratory failure (not Type 2)? Fibrosis thickens the alveolar-capillary membrane, impairing diffusion. CO2 diffuses ~20× faster than O2 (higher diffusion coefficient and solubility), so CO2 clearance is maintained even through a thickened membrane, while O2 transfer fails. Hence: hypoxaemia (↓PaO2) but normal or low PaCO2 (hyperventilation from respiratory drive). Type 2 only occurs very late when respiratory muscle fatigue supervenes.

Cardiac involvement (~20%): pericarditis, conduction abnormality, cor pulmonale. ^[1]

Oesophageal involvement (50–80%): scleroderma-like dysmotility. ^[1]

Raynaud's phenomenon: occurs early ± digit autoamputation in severe Raynaud. ^[1]

Characteristically NO severe renal involvement; may have membranous nephropathy. ^[1]

"Diagnostic shift": could later evolve into another CTD (e.g., SLE). ^[4]

This is a unique "complication" of MCTD:

• Approximately 10–30% of patients evolve into a defined CTD over 10–20 years
• Most commonly evolves into SLE (acquisition of anti-dsDNA, development of nephritis) or SSc (progressive scleroderma, PAH)
• This means ongoing surveillance and periodic re-evaluation of the diagnosis is mandatory
• The appearance of anti-Sm or high-titre anti-dsDNA should prompt reclassification

Neurological involvement is uncommon in MCTD ^[1], but when it occurs:

Complications of chronic steroid use are a significant source of morbidity in MCTD. ^[2]